RO (RO) Stock Price, News & Analysis

Name: RO (RO) Financial Data & Stock Overview
Creator: Stock Titan
License: https://www.stocktitan.net/terms-of-use

Company Description

This page collects what Stock Titan holds for RO, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

Performance 1 year

$0.0

Market Cap

0.0

Shares outstanding

Latest News

View All

March 22, 2021

0.00%

Genentech Provides Update on Tominersen Program in Manifest Huntington's Disease

March 22, 2021

0.00%

Pivotal Phase III Study Shows Genentech’s Tecentriq Helped People With Early Lung Cancer Live Longer Without Their Disease Returning

clinical trial

March 16, 2021

0.00%

New 2-Year Data Show Genentech’s Evrysdi (risdiplam) Continues to Demonstrate Improvement or Maintenance of Motor Function in People Aged 2-25 With Type 2 or Type 3 Spinal Muscular Atrophy (SMA)

March 11, 2021

0.00%

Genentech Provides Update on the Phase III REMDACTA Trial of Actemra Plus Veklury in Patients With Severe COVID-19 Pneumonia

clinical trial covid-19

March 8, 2021

0.00%

Genentech Provides Update on Tecentriq U.S. Indication in Prior-Platinum Treated Metastatic Bladder Cancer

March 4, 2021

0.00%

Genentech’s Actemra Becomes the First Biologic Therapy Approved by the FDA for Slowing the Rate of Decline in Pulmonary Function in Adults With Systemic Sclerosis-Associated Interstitial Lung Disease, a Rare, Debilitating Condition

fda approval

RO has 10 recent news articles. Key topics include clinical trial, covid-19, fda approval. View all RO news →

SEC Filings

View All

No SEC filings available for RO.

Financial Highlights

—

Revenue (latest FY)

—

Net Income (latest FY)

—

Diluted EPS (latest FY)

—

Operating Cash Flow

—

Net Profit Margin

—

Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months